高血圧を制御するためのカリブ海および南アメリカのチームベースの戦略 (CATCH)
コロンビアとジャマイカにおける高血圧管理のためのチームベースのケア戦略の実施と拡大
The CATCH cluster randomized trial will test the effectiveness and implementation outcomes of implementing and scaling up the 2017 American Heart Association and 2021 World Health Organization hypertension guidelines through a team-based care approach for blood pressure control in Colombia and Jamaica.
調査の概要
状態
詳細な説明
The CATCH Study includes a two-year UG3 Planning Phase and a four-year UH3 Implementation Phase. In the UH3 Implementation Phase, we will first conduct a cluster randomized implementation trial to test the effectiveness and implementation of a team-based care strategy to implement a single-pill combination strategy for hypertension control among patients with hypertension in 40 clinics from Colombia and Jamaica (20 in each country). Twenty clinics will be randomized to the team-based care intervention and 20 to provider training intervention. A total of 1,680 patients (42 per clinic) with uncontrolled hypertension will be recruited into the study and followed for 18 months for effectiveness and implementation outcomes. A post-intervention study visit will take place 6 months after the end of the 18-month intervention to evaluate the sustainability of the implementation strategies. We will subsequently conduct a pre- and post- scale-up comparison study to implement the team-based care strategy in all remaining public primary care clinics that provide chronic disease management in Jamaica and primary care clinics in the seven participating departments in Colombia. A pre- and post- scale-up comparison design will be used to assess barriers and implementation outcomes before and 12 months after the scale-up intervention at the clinic, primary care physician, nurse/pharmacist, and community health worker (CHW) levels.
研究の種類
入学 (実際)
段階
- フェーズ 3
連絡先と場所
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion criteria for clinics:
- Serving >300 hypertensive patients during the previous year
- Clinic visits and BP medications are free of charge to patients
- Not sharing physicians, nurses, pharmacists, or community health workers (CHWs) with other clinics
Inclusion criteria for participants:
- Men or women aged ≥ 21 years who receive primary care from participating clinics
- Average untreated BP ≥140/90 mm Hg among individuals without a history of clinical cardiovascular disease (CVD), chronic kidney disease (CKD), or diabetes; average untreated BP ≥130/80 mm Hg among individuals aged ≥65 years or those with clinical CVD, CKD, or diabetes; or average treated BP ≥130/80 mm Hg from six BP readings at two screening visits
- No prior hospitalization for heart failure
- No stage 4 or 5 chronic kidney disease (estimated glomerular filtration rate <30 ml/min/1,73m2, chronic dialysis, or transplant)
- Not pregnant or planning to become pregnant in the next 18 months
- Able and willing to give informed consent
- No plans to change primary care clinic in the next 18 months
- Not an immediate family member of staff at the primary care clinic
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Implementing Single-pill Combination by Team-based Care
The core component of the intervention is a single-pill combination therapy recommended by the 2017 American College of Cardiology (ACC)/American Heart Association (AHA) Clinical Practice Guideline for High Blood Pressure and the 2021 World Health Organization (WHO) Hypertension Guideline. Using a team-based care model, a physician-nurse-CHW team will work with patients to implement single-pill combination therapy in all intervention clinics. Team-based care components will include health care team training, home BP monitoring, BP audit and feedback, and CHW-led health coaching on lifestyle modification and medication adherence. |
The core component of the intervention is single-pill combination recommended by the 2017 American College of Cardiology (ACC)/American Heart Association (AHA) Clinical Practice Guideline for High Blood Pressure and the 2021 World Health Organization (WHO) Hypertension Guideline. Using a team-based care model, a physician-nurse-CHW team will work with patients to implement clinical guideline-based treatment in all intervention clinics. Team-based care components will include health care team training, home BP monitoring, BP audit and feedback, and CHW-led health coaching on lifestyle modification and medication adherence. |
|
アクティブコンパレータ:Enhanced Usual Care
We will train the primary care physicians, nurses, and other clinic staff in performing standardized BP measurements. We will offer physician education on clinical guidelines for hypertension management and issue continuing medical education credits. Patient educational materials will be distributed. We will not conduct any other interventions in the enhanced usual care clinics. |
We will train the primary care physicians, nurses, and other clinic staff in performing standardized BP measurements. We will offer physician education on clinical guidelines for hypertension management and issue continuing medical education credits. Patient educational materials will be distributed. We will not conduct any other interventions in the enhanced usual care clinics. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Net difference in mean change of systolic blood pressure
時間枠:18 months
|
Differences in mean change of systolic BP from baseline to 18 months between intervention and control groups |
18 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Difference in blood pressure control (<130/80 mm Hg)
時間枠:18 months
|
Difference in the proportion of patients with systolic BP <130 mm Hg and diastolic BP <80 mm Hg between intervention and control groups at 18 months |
18 months
|
|
Net difference in mean change of diastolic blood pressure
時間枠:18 months
|
Differences in mean change of diastolic BP from baseline to 18 months between intervention and control groups |
18 months
|
|
Side effects
時間枠:18 months
|
Differences in medication side effects between intervention and control groups will be assessed by survey. A list of common side effects associated with high blood pressure will be asked of participants to collect presence and frequency of side effects. |
18 months
|
|
Health-related quality of life
時間枠:18 months
|
Differences in health-related quality of life (measured by EQ-SD and SF-12) between intervention and control groups |
18 months
|
|
Cost-effectiveness
時間枠:18 months
|
Incremental direct costs per additional percentage of hypertension control |
18 months
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Acceptability
時間枠:18 months
|
Measured by validated survey |
18 months
|
|
Adoption
時間枠:Baseline
|
Defined as % of clinics adopting intervention components |
Baseline
|
|
Appropriateness
時間枠:18 months
|
Measured by validated survey |
18 months
|
|
Feasibility (suitability)
時間枠:Baseline
|
Measured by validated survey |
Baseline
|
|
Fidelity
時間枠:18 months
|
% of each intervention component delivered per protocol |
18 months
|
|
Implementation Costs
時間枠:18 months
|
Defined as all costs associated with implementation and assessed from administrative data |
18 months
|
|
Penetrance
時間枠:18 months
|
Defined as % of providers using the intervention approach |
18 months
|
|
Sustainability
時間枠:18 months
|
% of clinics maintaining intervention |
18 months
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Patricio López-Jaramillo, MD, PhD、Universidad de Santander
- 主任研究者:Jiang He, MD, PhD、Tulane University
- 主任研究者:Marshall Tulloch-Reid, MBBS, DSc、The University of The West Indies
出版物と役立つリンク
便利なリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
- UG3HL152373 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Our study data sharing plan will comply with all NIH policies for data sharing. Data sharing will be executed through the centralized NIH data repository and will be implemented in a timely manner. Study data, including data from baseline and follow-up visits, will be prepared for transmission to the NHLBI data repository - the Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC). Data will be prepared by the study data manager/biostatistician and sent to the Program Official for review prior to release. These data will be free of identifiers that allow identification of individual research participants either directly or through "deductive disclosure." We are very open to sharing data enthusiastically with the general scientific community, since we also believe in the added value of other investigators working on these data.
IPD 共有時間枠
Data sets will be submitted to the study's NHLBI Program Official no later than 3 years after the end of the final patient follow-up visit or 2 years after the main paper of the trial has been published, whichever comes first.
IPD 共有アクセス基準
We will offer, through our public access website, opportunities for outside investigators to collaborate with us using complete study data.
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。